Funded Biotechnology Startups in Carlsbad
The 12 Carlsbad biotechnology companies shown here closed rounds between January 2021 and August 2025.
The 12 Carlsbad biotechnology companies shown here closed rounds between January 2021 and August 2025. Four of those rounds came in the first eight months of 2025: Lineage Cell Therapeutics raised $12M in late August, Capienda Biotech $330K a week earlier, and Qualigen and Palisade Bio closed rounds of $5M and $4M respectively in July. Among all 12, Allez Health's $60M Series A in May 2024 is the largest disclosed amount.
Eight of the 12 rounds carry a Series Unknown classification, consistent with convertible notes, PIPE transactions, and at-the-market offerings common in small-cap public biotech. The named staged rounds include Jumpcode Genomics' $21M Series B (January 2021), ChromaCode's undisclosed Series D (June 2023), and Progenity's $20M Post-IPO Equity (October 2021). Disclosed deal sizes span from $330K to $60M, with three rounds — M2 Ingredients, ALZpath, and ChromaCode — listing undisclosed amounts.
Most recent rounds
12 shownRelated listings
Frequently asked
What is the largest disclosed round among these Carlsbad biotech companies?
Allez Health raised a $60M Series A in May 2024, the largest disclosed amount in this dataset. The next largest are Jumpcode Genomics' $21M Series B from January 2021 and Progenity's $20M Post-IPO Equity from October 2021.
How many of these companies closed rounds in 2025, and which ones?
Four companies closed rounds through August 2025: Lineage Cell Therapeutics ($12M), Qualigen ($5M), Palisade Bio ($4M), and Capienda Biotech ($330K). All four carry a Series Unknown classification.
What round types appear most frequently in this group?
Series Unknown accounts for 8 of the 12 rounds, which typically reflects convertible notes, PIPE transactions, or at-the-market offerings. The remaining four are a Series A (Allez Health), a Series B (Jumpcode Genomics), a Series D (ChromaCode), and a Post-IPO Equity round (Progenity).
Are any of these companies at a post-IPO stage?
Progenity closed a $20M Post-IPO Equity round in October 2021, indicating it was publicly traded at that time. No other company in this dataset carries a Post-IPO stage designation.
What is the spread of disclosed deal sizes, and how many rounds are undisclosed?
Disclosed amounts range from $330K (Capienda Biotech, August 2025) to $60M (Allez Health, May 2024). Three rounds — M2 Ingredients, ALZpath, and ChromaCode — list undisclosed amounts.
Know which startups just got funded. Every week.
Fresh funding rounds, new companies, and the sectors moving fastest — in your inbox every Monday morning.
Free. Sent every Monday. Unsubscribe anytime.